Calkins B.M., Mendelhoff A.I. (1995) The epidemiology of idiopathic inflammatory bowel disease. Inflammatory bowel disease. 4th ed , Kirsner JB, Shorter RG, eds. Baltimore: Williams & Wilkins; 31-68.
Binder V. (1998) Genetic epidemiology in inflammatory bowel disease. Dig Dis 16:351-355.
Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., Almer S., Tysk C., O’Morain C., Gassull M., Binder V., Finkel Y., Cortot A., Modigliani R., Laurent-Puig P., Gower-Rousseau C., Macry J., Colombel J.F., Sahbatou M., Thomas G. (2001) Association of NOD2/CARD15 leucin-rich repeat variants with susceptibility to Crohn disease. Nature 411:599-603.
Ogura Y., Bonen D.K., Inohara N., Nicolae D.I., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H., Achkar J.P., Brant S.R., Bayless T.M., Kirschner B.S., Hanauer S.B., Nunez G., Cho J.H. (2001) A frameshift mutation in NOD2/CARD15 associated with susceptibility to Crohn disease. Nature 411:603-606.
Ogura Y., Inohara N., Benito A., Chen F.F., Yamaoka S., Nunez G. (2001) NOD2/CARD15, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB. J Biol Chem 276:4812-4818.
Targan S.R., Hanauer S.B., Van Deventer S.J.H., Mayer L., Present D.H., Braakman T.A.J., DeWoody K.L., Schaible T.F., Rutgeerts P. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn disease. N Engl J Med 337:1029-1035.
Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., Van Hogezand R.A., Podolsky D.K., Sands B.E., Braakman T., DeWoody K.L., Schaible T.F., Van Deventer S.J. (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398-1405.
Rutgeerts P., D’Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H., Mayer L., Van Hogezand R.A., Braakman T., DeWoody K.L., Schaible T.F., Van Deventer S.J.H. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 117:761-769.
Mascheretti S., Hampe J., Sfikas N., Kuhbacher T., Andus T., Herfarth H., Foelsch U., Scheiber S. (2001) Pharmcacogenetic association between the TNF receptor 2 genotype and response to infliximab treatment in Crohn’s disease. Gastroenterology 120:A362.
Taylor K.D., Plevy S.E., Yang H., Landers C.J., Barry M.J., Rotter J.I., Targan S.R. (2001) ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn’s disease. Gastroenterology 120:1347-1355.
Hampe J., Cuthbert A., Croucher P.J.P., Mirza M.M., Mascheretti S., Fisher S., Frenzel H., King K., Hasselmeyer A., MacPherson A.J.S., Bridger S., Van Deventer S., Forbers A., Nikolaus S., Lennard-Jones J.E., Foelsch U.R., Krawczak M., Lewis C., Schreiber S., Mathew C.G. (2001) Association between insertion mutation in NOD2/CARD15 gene and Crohn’s disease in German and British populations. Lancet 357:1925-1928.
Wardle T.D., Hall L., Turnberg L.A. (1992) Use of coculture of colonic biopsies to investigate the release of eicosanoids by inflamed and uninflamed mucosa from patients with inflammatory bowel disease. Gut 33:1644-1651.
Riley S.A., Mani V., Goodman M.J., Dutt S., Herd M.E. (1991) Microscopic activity in ulcerative colitis: What does it mean?. Gut 32:174-178.
Reimund J.M., Wittersheim C., Dumont S., Muller C.D., Kennet J.S., Baumann R., Poindron P., Duclos B. (1996) Increased production of tumor necrosis factor-α, interleukin-β, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn’s disease. Gut 39:684-689.
Hugot J.P., Laurent-Puig P., Gower-Rousseau C., Olson J.M., Lee J.C., Beaugerie L., Naom I., Dupas J.L., Van Gossum A., Orholm M., Bonaiti-Pellie C., Weissenbach J., Mathew C.G., Lennard-Jones J.E., Cortot A., Colombel J.F., Thomas G. (1996) Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature 379:821-823.
